Study endpoints
The primary endpoint was the rate of vertical transmission, defined as either positive neonatal IgM serology, positive neonatal IgG serology with a seronegative mother or positive neonatal SARS-COV-2 PCR. Humoral immune response was also evaluated, including the rate of positive mothers for each tested antibody and antibody levels by time between infection and delivery.
Correlation between antibody levels and clinical manifestation of COVID-19 was also evaluated as well as demographic and pregnancy characteristics and data regarding fetal malformations.